Organogenesis Celebrates Product Acquisitions; Highlights New Research at SAWC Spring 2017

CANTON, Mass. and SAN DIEGO, April 6, 2017 /PRNewswire/ -- This week, during the 30^th Annual Symposium on Advanced Wound Care Spring|Wound Healing Society meeting (SAWC Spring|WHS), Organogenesis will celebrate company milestones – including the recent acquisition of NuTech Medical and the three-year anniversary of the Dermagraft® acquisition – and highlight new products and research at the nation's largest interdisciplinary wound care forum, held April 5-9 in San Diego.

"As we celebrate the third anniversary of Organogenesis manufacturing Dermagraft right here in San Diego, and all that this product has done to advance the healing of chronic diabetic foot ulcers, it seems only fitting that we are also unveiling the acquisition of NuTech Medical, a collaboration that will expand our product portfolio into the surgical biologics arena, and increase our wound care product portfolio to include a best-in-class amniotic product," said Gary S. Gillheeney, Sr., President and CEO of Organogenesis.

Organogenesis Inc., a commercial leader in the field of regenerative medicine focusing on advanced wound care and surgical biologics, will feature its entire product portfolio at booth #405. The company's recently acquired NuTech Medical Surgical Division will also be featured at booth #104.

Scientific presentations will feature Organogenesis products; and in-booth lectures (at Booth #405) will feature research and case studies that cover the phases of wound healing.

POSTER PRESENTATIONS OF INTEREST INCLUDE:

Active Biofilm Management with Purified 2-layer Type 1 Native Porcine Collagen Matrix Embedded with polyhexamethylene biguanide (PHMB)

Clinton Schafer, DPM, Kenda Eckdahl, RN

Successful Healing of Complex Wounds With Exposed Tendon Using a Porcine Collagen Matrix Containing PHMB

Shaun Carpenter, MD, CWSP; Rebecca Hunt, APRN, CWS; Amanda Estapa, APRN,CWS; Brandi Flanagan, APRN,FNP-C; and Todd Shaffett, APRN,CWS

Cryopreserved Human Amniotic Suspension Allograft Encourages Polarization of Monocytes to an Anti-Inflammatory M2 Phenotype

Jeremy B. Vines, John P. McQuilling, and Katie C. Mowry

Proteomic Comparison of Amnion and Chorion and evaluation of the effects of processing on placental membranes

John P. McQuilling, Jeremy B. Vines, and Katie C. Mowry

Use of a Fresh Amniotic Membrane to Treat a Diverse Population of Wounds

Brock A. Liden DPM

Evaluation of the Mechanisms of Actions Treating Chronic Wounds with Hypothermically Stored Amnion

John P. McQuilling, Jeremy B. Vines, and Katie C. Mowry

Hypothermically Stored Amniotic Allograft for the Treatment of Diabetic Foot Ulcers

Michael Younes DPM, and John P. McQuilling Ph.D

Hypothermically Stored Amniotic Allograft for the Treatment of Severe Chronic Wounds

Tracey A. Culbertson M.D

Use of fresh hypothermically Stored Amnion for the treatment of a chronic scalp wound with exposed bone

Dianne Rudolph, GNP

About Organogenesis
Headquartered in Canton, Massachusetts, Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis' versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.  For more information, visit www.organogenesis.com.

CONTACT:
Angelyn Lowe
(781) 830-2353
[email protected]

SOURCE Organogenesis Inc.

Related Links

http://www.organogenesis.com